Results 101 to 110 of about 17,592 (206)
Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs
Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri +10 more
wiley +1 more source
Palbociclib in hormone-receptor–positive advanced breast cancer
, 2015 Background Growth of hormone-receptor–positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle.
M Koehler (13283067) +13 more
core
Ferroptosis in breast cancer: From adipocyte–immune–iron regulation to therapeutic application
Clinical and Translational Medicine, Volume 16, Issue 6, June 2026.Ferroptosis in breast cancer is regulated by an integrated adipocyte–immune–iron network rather than by tumour‐intrinsic pathways alone. Adipocyte‐derived lipid substrates and redox metabolites, immune‐cell‐mediated cytokine signalling and iron‐dependent oxidative stress collectively shape a dynamic ferroptosis ecosystem that can shift tumours towards ...
Juan Sun, Yang Qu, Ru Yao, Yidong Zhou
wiley +1 more source
, 2020 The efficacy of a selective CDK4/6 inhibitor (palbociclib) was evaluated in various preclinical models of nasopharyngeal carcinoma (NPC) including three NPC cell line (two newly established) and three newly established patient-derived xenografts (PDXs ...
Xue, Zhichao, 薛志超
core
, 2017 Estrogen receptor-positive (HR+) breast cancer is the most common form of breast cancer that is accountable for the majority of breast cancer mortality.
Saranya Chumsri +3 more
core +1 more source
, 2018 Introduction The addition of palbociclib to letrozole improves progression free survival (PFS) and response rates compared to letrozole alone in the 1st line treatment of hormone receptor positive advanced breast cancer.
J Helou, J Raphael, DM Naimark
core +1 more source
Gastric Cancer: Pathobiology and Therapeutics
MedComm, Volume 7, Issue 6, June 2026.Gastric cancer is a multistep process driven by the interplay of microbial virulence, host epithelial injury, and evolving molecular reprogramming. Initiation involves pathogen‐induced epigenetic alterations and the early subversion of key oncogenic signaling networks, facilitating the transition from chronic injury to metaplasia and malignant ...
Ruixian Yu +16 more
wiley +1 more source
Metabolic Regulation of Immune Responses: Molecular Mechanisms, Diseases, and Therapeutic Targets
MedComm, Volume 7, Issue 6, June 2026.FBP1 loss drives immune evasion and therapy resistance by enhancing glycolysis, STAT3 activation, and PD‐L1 expression, leading to T cell exhaustion and NK cell inhibition. FBP1 restoration, via LNP‐mRNA or epigenetic modulation, reverses these immunosuppressive effects, reactivates cytotoxic T cells, promotes M1 macrophage polarization, and enhances ...
Chunwei Li +10 more
wiley +1 more source
The Dual Role of Autophagy in Cancer: Mechanisms and Therapeutic Strategies
MedComm – Oncology, Volume 5, Issue 2, June 2026.Autophagy is a conserved cellular process degrading dysfunctional organelles and protein aggregates to maintain cell homeostasis, and it exhibits context‐dependent duality in cancer. Autophagy functions as a critical tumor‐suppressive mechanism by preventing DNA damage and mutation during tumor initiation.
Xiang‐Zheng Gao +4 more
wiley +1 more source
Characterizing Metabolic Alterations in Palbociclib-Resistant ER+ Breast Cancer
Characterizing Metabolic Alterations in Palbociclib-Resistant ER+ Breast Cancer Jessica Shunnarah1, Susan M. Dougherty2, Yoannis Imbert-Fernandez3 1ULBB Program, 2Department of Medicine, University of Louisville Abstract Diverse mechanisms of ...
Imbert-Fernandez, Yoannis +2 more
core